Amgen and BioLabs LA Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket
Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in Southern California. Nammi Therapeutics will receive one year of lab space at Biolabs LA as well as additional facility benefits and connections to Amgen scientific and business leaders.
The Amgen Golden Ticket winner was chosen by a team of Amgen scientific leaders at a virtual pitch event. Five finalists pitched their business plans before Amgen's internal committee that evaluated the strength and novelty of their scientific rationale, subject matter expertise, and business plan viability. View the file below for the full article.
Recent PostsSee All
Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and CEO of Nammi Therapeutics, and highlighted the most recent achie
The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the development of a safer, more tolerable alternative. The CIRM Board award
FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of Pancreatic Cancer. QXL 138AM is a Masked Immunocytokine targeting a masked interferon